Expand TAK Menu
TAK MENU

TAK Latest Press Releases

-- September 9, 2026 --

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life Business Wire 8:24 AM

-- August 28, 2026 --

Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera Business Wire 6:40 PM

-- August 24, 2026 --

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 Business Wire 2:36 AM

-- August 5, 2026 --

U.S. FDA Approves Takeda's ORZEYFUL (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 Business Wire 6:10 PM

-- July 30, 2026 --

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track Business Wire 2:37 AM

-- July 16, 2026 --

Takeda's Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies Business Wire 6:00 PM

-- July 12, 2026 --

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products Business Wire 7:00 PM

-- June 24, 2026 --

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO Business Wire 3:05 AM

-- June 23, 2026 --

Takeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations PRNewswire 8:00 AM

-- June 15, 2026 --

New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 Business Wire 12:00 PM

-- June 11, 2026 --

Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations Business Wire 7:00 AM

-- June 9, 2026 --

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease Business Wire 4:30 PM

-- May 18, 2026 --

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda Business Wire 5:51 PM

-- May 13, 2026 --

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results Business Wire 2:38 AM

-- May 4, 2026 --

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) Business Wire 8:00 AM
Market Data Delayed 15 Minutes